category,datetime,headline,id,image,related,source,summary,url
company,1768075033,Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences,138068855,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive agreement to acquire Ventyx Biosciences, Inc., which is a clinical-stage biopharmaceutical company that develops innovative oral therapies for patients with inflammatory-mediated diseases. Ventyx Biosciences, Inc. […]",https://finnhub.io/api/news?id=aaea7bc0000c4ffc4a221cab99d31981449f244b42c8b94a1ae79513ea59c22d
company,1768053576,The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth,138068856,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady",https://finnhub.io/api/news?id=8b1d9c99be103cbc679e34b532ea70b12e59e54f629b773f57c72a0403ed1f73
company,1768051897,The rise of obesity pills,138064407,https://image.cnbcfm.com/api/v1/image/108250804-original_1.jpeg?v=1767994635&w=1920&h=1080,LLY,CNBC,"2026 kicked off with the introduction of the Wegovy pill, the first ever non-injectable GLP-1 for obesity, from drugmaker Novo Nordisk. Competitors like Eli Lilly are racing to get their own versions of the drug on the market as analysts expect obesity pills to be widely sought after in the coming years. CNBC's Annika Kim Constantino breaks down why this is such a significant step for the industry. Watch the video to learn more.",https://finnhub.io/api/news?id=f226231b7dbb12cde1a4c479d9cbd124ad0f960cf0ec02e4e30dbcf548484364
company,1768048572,Is Fidelity’s Health Care ETF A Good Buy Right Now?,138068857,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,LLY,Yahoo,"Healthcare investing offers defensive characteristics during market turbulence, yet regulatory uncertainty and political risk can trigger sudden selloffs. For investors seeking pure healthcare exposure without picking individual stocks, Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) provides a low-cost entry point to this complex sector. What FHLC Delivers: Sector Exposure With a Concentration Problem FHLC tracks ... Is Fidelity’s Health Care ETF A Good Buy Right Now?",https://finnhub.io/api/news?id=110bb8d9ed0b300793a338341ac492cac84e367249b4415215fcd0eb2297f9dd
company,1768032001,2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market,138057241,https://image.cnbcfm.com/api/v1/image/108231152-17640105232025-11-24t185245z_617754530_rc263iabxpyr_rtrmadp_0_novo-nordisk.jpeg?v=1764010568&w=1920&h=1080,LLY,CNBC,"Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year. ",https://finnhub.io/api/news?id=0ef44fbf4b4de83c0e82bc17f6a38c818f9abb8935eb227d5b1980953b744477
